- Home
- BDRX
as 05-10-2024 4:00pm EST
$.
-
$.
-.%
Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
| Founded: | 2000 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 6.6M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.67 - $20.40 | Next Earning Date: | 05-21-2024 |
| Revenue: | $482,278 | Revenue Growth: | -34.08% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Latest Biodexa Pharmaceuticals plc American Depositary Shs News
BDRX Breaking Stock News: Dive into BDRX Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 days ago
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition
GlobeNewswire
12 days ago
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
GlobeNewswire
16 days ago
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire
23 days ago
Preliminary Results for the Year Ended 31 December 2023
ACCESSWIRE
a month ago
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
ACCESSWIRE
2 months ago
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
GlobeNewswire
3 months ago
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
GlobeNewswire
3 months ago